 "Cipla invests additional $ 3 million in US's Chase Pharmaceuticals")
The company in May 2014 had invested $1.5 million to acquire 14.6% stake in Chase Pharmaceuticals.
"Cipla (EU) Ltd, UK, a wholly-owned subsidiary of the company made an additional investment of $3 million in Chase Pharmaceuticals towards full settlement of its obligation under the agreement arrangement for investment in Chase," Cipla said in a BSE filing.
Also Read
Consequently, Cipla UK's total investment in Chase would aggregate to approximately $5.12 million for a 16.7% stake on a fully diluted basis.
As per the agreement in May, Cipla had said it will make an additional $4.5 million investment in Chase upon achievement of certain milestones in this direction.
The investment done through Cipla (EU) Ltd, UK, was part of $21 million syndicate to finance Phase 2a and Phase 2b clinical trials for Chase's lead drug CPC 201 for treating the disease.
Other investors in the syndicate were Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC.
The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%